ReviewNanomedicine : nanotechnology, biology, and medicine2015
Nanomedicine in the ROS-mediated pathophysiology: Applications and clinical advances.
Review in Nanomedicine : nanotechnology, biology, and medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Pathological Signal-Responsive Nanoplatforms for Sepsis: Integrating Biomarker Sensing With Spatiotemporal Drug Delivery and Immunomodulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Scavenging of reactive oxygen and nitrogen species using nanoparticles and their applications in disease management.RSC advances · 2025Review
- Nanomedicine Solutions for Alzheimer's Disease: A Critical Review of Therapeutic Nanoparticle Strategies.ACS omega · 2025Review
- A cerium nanocluster for effective alleviation of inflammatory bowel disease by scavenging RONS and regulating gut microbiome.Materials today. Bio · 2025Article
- Utilizing reactive oxygen species-scavenging nanoparticles for targeting oxidative stress in the treatment of ischemic stroke: A review.Open medicine (Warsaw, Poland) · 2024Review
- Polydopamine-Cloaked Nanoarchitectonics of Prussian Blue Nanoparticles Promote Functional Recovery in Neonatal and Adult Ischemic Stroke Models.Biomaterials research · 2024Article
- Titanium Dioxide Nanoparticles: Effects on Development and Male Reproductive System.Nanomaterials (Basel, Switzerland) · 2023Article
- Role of microRNA-34a in blood-brain barrier permeability and mitochondrial function in ischemic stroke.Frontiers in cellular neuroscience · 2023Review
- ROS-scavenging materials for skin wound healing: advancements and applications.Frontiers in bioengineering and biotechnology · 2023Review
- Review
- Green Synthesis and Characterization of ZnO Nanoparticles UsingAntioxidants (Basel, Switzerland) · 2022Article
- Antioxidant and Anti-Inflammatory Properties of Rubber Seed Oil in Lipopolysaccharide-Induced RAW 267.4 Macrophages.Nutrients · 2022Article
- Review
- Nanozymes-recent development and biomedical applications.Journal of nanobiotechnology · 2022Review
- Reactive Oxygen Species in the Adverse Outcome Pathway Framework: Toward Creation of Harmonized Consensus Key Events.Frontiers in toxicology · 2022Review
- Effects of Peroxiredoxin 6 and Its Mutants on the Isoproterenol Induced Myocardial Injury in H9C2 Cells and Rats.Oxidative medicine and cellular longevity · 2022Article
- Reactive-oxygen-species-scavenging nanomaterials for resolving inflammation.Materials today. Bio · 2021Review
- Reactive Oxygen Species-Regulating Strategies Based on Nanomaterials for Disease Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Combined Cornus Officinalis and Paeonia Lactiflora Pall Therapy Alleviates Rheumatoid Arthritis by Regulating Synovial ApoptosisFrontiers in pharmacology · 2021Article
- Encapsulation of Oleuropein in Nanostructured Lipid Carriers: Biocompatibility and Antioxidant Efficacy in Lung Epithelial Cells.Pharmaceutics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Reactive oxygen species (ROS) are important in regulating normal cell physiological functions, but when produced in excess lead to the augmented pathogenesis of various diseases. Among these, ischemia reperfusion injury, Alzheimer's disease and rheumatoid arthritis are particularly important. Since ROS can be counteracted by a variety of antioxidants, natural and synthetic antioxidants have been developed. However, due to the ubiquitous production of ROS in living systems, poor in vivo efficiency of these agents and lack of target specificity, the current clinical modalities to treat oxidative stress damage are limited. Advances in the developing field of nanomedicine have yielded nanoparticles that can prolong antioxidant activity, and target specificity of these agents. This article reviews recent advances in antioxidant nanoparticles and their applications to manage oxidative stress-mediated diseases. FROM THE CLINICAL EDITOR: Production of reactive oxygen species (ROS) is a purely physiological process in many disease conditions. However, excessive and uncontrolled production will lead to oxidative stress and further tissue damage. Advances in nanomedicine have provided many novel strategies to try to combat and counteract ROS. In this review article, the authors comprehensively highlighted the current status and future developments in using nanotechnology for providing novel therapeutic options in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.